Agreed there is Massive potential in those 2 drugs, its how the Company is run with such little cash flow and high cash burn.
Recent case in point is RCE, check the graph.
IMO its trying to do Everything Everywhere All At Once and will not have the cashflow to complete without another Cap raising.
Ann: Nature Cancer Publishes Results of PXS Garvin Collaboration, page-9
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.002(5.00%) |
Mkt cap ! $57.67M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.3¢ | 4.0¢ | $48.01K | 1.160M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1025000 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 461843 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |